Literature DB >> 21885587

Direct costs of bipolar disorder versus other chronic conditions: an employer-based health plan analysis.

Mark D Williams1, Nilay D Shah, Amy E Wagie, Douglas L Wood, Mark A Frye.   

Abstract

OBJECTIVE: This study was a retrospective data-based analysis of health care utilization and costs for patients diagnosed as having bipolar disorder compared with patients with diagnoses of depression, diabetes, coronary artery disease, or asthma.
METHODS: Data were from an employer-based health plan. Consistent diagnosis and continuous enrollment from 2004 to 2007 were used to identify the study population (total N = 7,511), including those with bipolar disorder (N = 122), depression (N = 1,290), asthma (N = 2,770), coronary artery disease (N = 1,759), diabetes (N = 1,418), and diabetes with coronary artery disease (N = 455). Resource utilization quantified as cost (total, specialty care, psychiatric outpatient) and number of visits (specialty care and outpatient psychiatric care) was compared across groups.
RESULTS: Patients with bipolar disorder had higher adjusted mean per member per month (PMPM) costs than any other comparison group except for those with both diabetes and coronary artery disease. The cost was predominantly related to pharmacy costs and both inpatient and outpatient psychiatric care. A subset of 20% of patients with bipolar disorder accounted for 64% of the total costs. This subgroup of patients was more likely to be female, to have frequent hospital stays, and to have a higher number of comorbidities. Depressed patients, in contrast to bipolar disorder patients, had higher adjusted mean PMPM costs in primary care and nonpsychiatric inpatient costs.
CONCLUSIONS: Health care costs for bipolar disorder exceeded those for several common chronic illnesses. These data provide further evidence for employers, insurers, and providers to seek innovative models to deliver effective and efficient care to individuals with bipolar illness.

Entities:  

Mesh:

Year:  2011        PMID: 21885587     DOI: 10.1176/ps.62.9.pss6209_1073

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  11 in total

Review 1.  Diagnosis and treatment of bipolar disorders in adults: a review of the evidence on pharmacologic treatments.

Authors:  Michael W Jann
Journal:  Am Health Drug Benefits       Date:  2014-12

Review 2.  Integrating bipolar disorder management in primary care.

Authors:  Amy M Kilbourne; David E Goodrich; Allison N O'Donnell; Christopher J Miller
Journal:  Curr Psychiatry Rep       Date:  2012-12       Impact factor: 5.285

3.  Primary care and behavioral health practice size: the challenge for health care reform.

Authors:  Mark S Bauer; Deane Leader; Hyong Un; Zongshan Lai; Amy M Kilbourne
Journal:  Med Care       Date:  2012-10       Impact factor: 2.983

4.  Estimating incremental costs with skew: a cautionary note.

Authors:  Linnea A Polgreen; John M Brooks
Journal:  Appl Health Econ Health Policy       Date:  2012-09-01       Impact factor: 2.561

Review 5.  Can bipolar disorder be viewed as a multi-system inflammatory disease?

Authors:  Marion Leboyer; Isabella Soreca; Jan Scott; Mark Frye; Chantal Henry; Ryad Tamouza; David J Kupfer
Journal:  J Affect Disord       Date:  2012-04-11       Impact factor: 4.839

Review 6.  Cost-of-illness studies for bipolar disorder: systematic review of international studies.

Authors:  Huajie Jin; Paul McCrone
Journal:  Pharmacoeconomics       Date:  2015-04       Impact factor: 4.981

7.  Association of Bipolar Disorder With Major Adverse Cardiovascular Events: A Population-Based Historical Cohort Study.

Authors:  Moein Foroughi; Jose R Medina Inojosa; Francisco Lopez-Jimenez; Farzane Saeidifard; Laura Suarez; Gorazd B Stokin; Miguel L Prieto; Walter A Rocca; Mark A Frye; Robert J Morgan
Journal:  Psychosom Med       Date:  2022-01-01       Impact factor: 4.312

8.  Gender differences, clinical correlates, and longitudinal outcome of bipolar disorder with comorbid migraine.

Authors:  Erika F H Saunders; Racha Nazir; Masoud Kamali; Kelly A Ryan; Simon Evans; Scott Langenecker; Alan J Gelenberg; Melvin G McInnis
Journal:  J Clin Psychiatry       Date:  2014-05       Impact factor: 4.384

9.  Aripiprazole in the acute and maintenance phase of bipolar I disorder.

Authors:  Melanie Zupancic; Misty L Gonzalez
Journal:  Ther Clin Risk Manag       Date:  2012-01-12       Impact factor: 2.423

Review 10.  Management of bipolar I depression: clinical utility of lurasidone.

Authors:  Lillian Jan Findlay; Peggy El-Mallakh; Rif S El-Mallakh
Journal:  Ther Clin Risk Manag       Date:  2015-01-08       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.